Kerry Holford
Stock Analyst at Berenberg Bank
(4.01)
# 1,709
Out of 4,575 analysts
237
Total ratings
59.6%
Success rate
9.1%
Average return
Main Sectors:
Stocks Rated by Kerry Holford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintained: Hold | $1,135 | $1,196.03 | -5.10% | 31 | Jul 16, 2026 | |
| LON: 0NZT UCB SA | Maintained: Buy | €130.00 → €305.00 | €240.88 | +26.62% | 3 | Jul 2, 2026 | |
| LON: 0QIU Novo Nordisk A/S | Maintained: Buy | kr 300.00 → kr 325.00 | kr 320.60 | +1.37% | 41 | Jun 17, 2026 | |
| ZLDPF Zealand Pharma A/S | Downgraded: Hold | $125 → $46 | $45.01 | +1.37% | 4 | Jun 16, 2026 | |
| PFE Pfizer | Maintained: Hold | $25 | $24.54 | +1.87% | 30 | May 8, 2026 | |
| LON: GSK GSK plc | Maintained: Hold | 2,000p | 1,920p | +4.19% | 49 | May 5, 2026 | |
| NVO Novo Nordisk | Maintained: Buy | $57 → $47 | $48.77 | -3.63% | 7 | Mar 11, 2026 | |
| NVS Novartis AG | Rated: Hold | $116 → $141 | $155.01 | -9.04% | 8 | Mar 6, 2026 | |
| GSK GSK plc | Maintained: Hold | $41 → $43 | $51.35 | -16.26% | 14 | Nov 25, 2025 | |
| SWX: NOVN Novartis AG | Maintained: Hold | CHF 89.00 → CHF 92.00 | CHF 126.90 | -27.50% | 40 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €105.00 → €120.00 | €76.03 | n/a | 3 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €1.60 | €1.85 | n/a | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $65 → $60 | $80.29 | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 100p | 42p | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | €150.00 | €139.15 | n/a | 1 | Apr 16, 2021 |
Eli Lilly and Company
Jul 16, 2026
Maintained: Hold
Price Target: $1,135
Current: $1,196.03
Upside: -5.10%
UCB SA
Jul 2, 2026
Maintained: Buy
Price Target: €130.00 → €305.00
Current: €240.88
Upside: +26.62%
Novo Nordisk A/S
Jun 17, 2026
Maintained: Buy
Price Target: kr 300.00 → kr 325.00
Current: kr 320.60
Upside: +1.37%
Zealand Pharma A/S
Jun 16, 2026
Downgraded: Hold
Price Target: $125 → $46
Current: $45.01
Upside: +1.37%
Pfizer
May 8, 2026
Maintained: Hold
Price Target: $25
Current: $24.54
Upside: +1.87%
GSK plc
May 5, 2026
Maintained: Hold
Price Target: 2,000p
Current: 1,920p
Upside: +4.19%
Novo Nordisk
Mar 11, 2026
Maintained: Buy
Price Target: $57 → $47
Current: $48.77
Upside: -3.63%
Novartis AG
Mar 6, 2026
Rated: Hold
Price Target: $116 → $141
Current: $155.01
Upside: -9.04%
GSK plc
Nov 25, 2025
Maintained: Hold
Price Target: $41 → $43
Current: $51.35
Upside: -16.26%
Novartis AG
Nov 18, 2025
Maintained: Hold
Price Target: CHF 89.00 → CHF 92.00
Current: CHF 126.90
Upside: -27.50%
May 16, 2025
Maintained: Buy
Price Target: €105.00 → €120.00
Current: €76.03
Upside: n/a
Apr 1, 2025
Maintained: Hold
Price Target: €1.60
Current: €1.85
Upside: n/a
Mar 24, 2025
Maintained: Hold
Price Target: $65 → $60
Current: $80.29
Upside: n/a
Mar 24, 2025
Maintained: Buy
Price Target: 100p
Current: 42p
Upside: n/a
Apr 16, 2021
Maintained: Hold
Price Target: €150.00
Current: €139.15
Upside: n/a